Hepatic toxicity during adjuvant cyclophosphamide, methotrexate and 5-Fluorouracil (CMF) in breast cancer

被引：0
|
作者：
Noberasco, C [1 ]
Peruzzotti, G [1 ]
Colleoni, M [1 ]
Nole, F [1 ]
deBraud, F [1 ]
Martinelli, G [1 ]
Goldhirsch, A [1 ]
机构：
[1] European Inst Oncol, Div Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
30P
引用
收藏
页码：7 / 7
页数：1
相关论文
共 50 条
  • [1] Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
    Batey, MA
    Wright, JG
    Azzabi, A
    Newell, DR
    Lind, MJ
    Calvert, AH
    Boddy, AV
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (08) : 1081 - 1089
  • [2] CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF)-INDUCED OCULAR TOXICITY
    LOPRINZI, CL
    LOVE, RR
    GARRITY, JA
    AMES, MM
    [J]. CANCER INVESTIGATION, 1990, 8 (05) : 459 - 465
  • [3] CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) ASSOCIATED OCULAR TOXICITY
    LOPRINZI, C
    HARTMANN, L
    AMES, M
    [J]. CLINICAL RESEARCH, 1988, 36 (03): : A497 - A497
  • [4] Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer
    Sitzia, J
    Huggins, L
    [J]. CANCER PRACTICE, 1998, 6 (01) : 13 - 21
  • [5] Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
    O'Byrne, KJ
    Koukourakis, MI
    Saunders, MP
    Salisbury, AJ
    Isaacs, R
    Varcoe, S
    Taylor, M
    Ganesan, TS
    Harris, AL
    Talbot, DC
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 1950 - 1956
  • [6] Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
    KJ O'Byrne
    MI Koukourakis
    MP Saunders
    AJ Salisbury
    R Isaacs
    S Varcoe
    M Taylor
    TS Ganesan
    AL Harris
    DC Talbot
    [J]. British Journal of Cancer, 1998, 77 : 1950 - 1956
  • [7] 5FU (5 fluorouracil) infusion duration and toxicity during CMF (cyclophosphamide, methotrexate, 5 fluorouracil) administration in adjuvant setting of breast cancer
    Capobianco, Alba M.
    Tartarone, Alfredo
    Coccaro, Mariarosa
    Di Leo, Pasquale
    Bochicchio, Annamaria
    Ardito, Raffaele
    Rionero, Crob
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 109 - 109
  • [8] CLINICAL CONTROLLED TRIAL IN ADVANCED BREAST-CANCER - CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL) VERSUS CMF+T (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL, TAMOXIFEN)
    HINDY, I
    [J]. NEOPLASMA, 1985, 32 (03) : 381 - 387
  • [9] ADRIAMYCIN, VINCRISTIN, CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL (AVCF) ADJUVANT TREATMENT OF BREAST-CANCER COMPARED TO TREATMENT WITH CYCLOPHOPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF)
    MATHE, G
    MISSET, JL
    PLAGNE, R
    BELPOMME, D
    LEMEVEL, B
    GUERRIN, J
    FUMOLEAU, P
    METZ, R
    DELGADO, M
    DEVASSAL, F
    ERIGUCHI, M
    SCHNEIDER, M
    REIZENSTEIN, P
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1985, 6 (02) : 168 - 168
  • [10] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    [J]. JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
12345